期刊文献+

紫杉醇脂质体联合卡培他滨治疗老年晚期三阴乳腺癌的临床效果探究

Clinical effect of paclitaxel liposome combined with capecitabine in the treatment of elderly patients with advanced triple negative breast cancer
原文传递
导出
摘要 目的 探析在老年晚期三阴乳腺癌患者治疗中应用紫杉醇脂质体联合卡培他滨的临床疗效.方法 回顾性分析我院收治的67例老年晚期三阴乳腺癌患者的各项资料,以治疗方案的不同进行分组,即单一应用紫杉醇脂质体治疗的患者纳入单一组(33例),而应用紫杉醇脂质体联合卡培他滨治疗的患者纳入联合组(34例).观察两组近期疗效、不良反应发生情况.结果 单一组、联合组总有效率分别为51.52%、76.47%,总有效率有显著差异(P<0.05).单一组、联合组不良反应发生率分别为45.45%、20.59%,联合组不良反应发生率更低(P<0.05).结论 应用紫杉醇脂质体联合卡培他滨治疗老年晚期三阴乳腺癌患者,不仅近期疗效理想,而且可减少胃肠道反应的发生.
出处 《首都食品与医药》 2021年第5期79-80,共2页 Capital Food Medicine
  • 相关文献

参考文献7

二级参考文献52

  • 1Berrada N , Delaloge S, Andre F. Treatment of triple-negative metastaticbreast cancer:toward individualized targeted treatments or chemosensitiza-tion?[J]. Ann Oncol,2010,21 Suppl 7:vii30-vii35.
  • 2Kim HR, Jung KH, Im SA, et al. Multicentre phase II trial of bevacizumabcombined with docetaxel-carboplatin for the neoadjuvant treatment oftriple-negative breast cancer (KCSG BR-0905) [J]. Ann Oncol,2013,24(6):1485-1490.
  • 3Silver DP , Richardson AL, Eklund AC , et al. Efficacy of neoadjuvantCisplatin in triple-negative breast cancer[J]. J Clin Oncol,2010,28(7):1145-1153.
  • 4Venkitaraman R. Triple - negative / basal - like breast cancer : clinical,pathologicand molecular features[J]. Expert Rev Anticancer Ther,2010,10(2):199-207.
  • 5Isakoff SJ, Mayer EL, He L, et, al. TBCRC009 : a Multicenter phase I clinical trial of platinum monotherapy with biomarker assessment in metastatic triple-negative breast cancer[J]. J Clin Oncol, 2015,33 (17) : 1902-1909.
  • 6O'Shaughnessy J, Schwartzberg L, Danso MA , et al. Phase III study ofiniparib plus gemcitabine and carboplatin versus gemcitabine andcarboplatin in patients with metastatic triple-negative breast cancer [Jj.J Clin Oncol, 2014,32( 34) : 3840-3847.
  • 7Biganzoli L,Coleman R,Minisini A , et al. A joined analysis of twoEuropean Organization for the Research and Treatment of Cancer(EORTC) studies to evaluate the role of pegylated liposomal doxorubicin(Caelyx) in the treatment of elderly patients with metastatic breastcancerfj]. Crit Rev Oncol Hematol, 2007,61 (1) :84-89.
  • 8Pierga JY,Fumoleau P,Brewer Y , et al. Efficacy and safety of singleagent capecitabine in pretreated metastatic breast cancer patients fromthe French compassionate use program[J]. Breast Cancer Res Treat,2004,88(2):117-129.
  • 9Wildiers H , Mauer M , Pallis A , et al. End points and trial design ingeriatric oncology research : a joint European organisation for researchand treatment of cancer-Alliance for Clinical Trials in Oncology-International Society Of Geriatric Oncology position article[J]. J Clin Oncol,2013,31(29):3711-3718.
  • 10Perez EA,Hillman DW,Dentchev T,et al. North central cancer treatmentgroup(NCCTG) N0432:phase II trial of docetaxel with capecitabine andbevacizumab as first-line chemotherapy for patients with metastatic breastcancer[J]. Ann Oncol,2010,21 (2) :269-274.

共引文献1232

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部